Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Join us! Registration is OPEN for the 2023 English Targeted Therapies Patient Forum!
dbrock
Author
Denise Brock
Image
TTF 2023 English header

Join us on SATURDAY, JULY 15th, 2023, for the 2023 Targeted Therapies Patient Forum

This virtual program is presented Live Online from 10 AM - 4 PM EDT

Register Now! 

In this 9th annual live patient forum, leading thoracic oncologists from around the world as well as lung cancer patients who are active within the patient advocacy community discuss subjects relevant to all targets as well as breakout sessions on rare mutations.

 

This 6-hour live virtual webinar is an opportunity for lung cancer patients and caregivers to hear from experts and participate in live virtual Q&A sessions.  The forum offers panel discussions, live Q&A sessions, and breakout sessions focused on rare mutations such as EGFR, ALK, ROS, RET and KRAS.  This event is free but registration is required and limited.  For more information visit the full AGENDAFaculty Bio's willl be available soon. 

2023 Targeted Therapies in Lung Cancer Patient Forum

***Subject to Change***

Event Chairs:   Sandip Patel, MD, Jessica Lin, MD

Topics include:

  • Biomarker Testing: The Fundamentals and The Challenges
  • Non-Metastatic Disease and Targeted Therapies
  • After or Adding To Targeted Therapy
  • Patient and Research Advocacy Presentation
  • Resistance Mechanisms and Re-Biopsies
  • Symptom Management and Palliative Care

   Breakout Session Rooms will include the following discussions:

  • EGFR
  • EGFR Ex 20, HER 2
  • ALK, ROS 1 
  • RET, Rare Fusions
  • KRAS
  • MET, BRAF

Each session includes full Panel Discussions and Q&A Sessions.  View the full AGENDA here. 


 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on